These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1095 related items for PubMed ID: 12490789

  • 1. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, Sirolimus Renal Function Study Group.
    Transplantation; 2002 Dec 15; 74(11):1560-7. PubMed ID: 12490789
    [Abstract] [Full Text] [Related]

  • 2. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J.
    Transplantation; 2001 Sep 15; 72(5):777-86. PubMed ID: 11571437
    [Abstract] [Full Text] [Related]

  • 3. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 4. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Jul 27; 76(2):364-70. PubMed ID: 12883194
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
    Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J.
    Transplantation; 1999 Nov 27; 68(10):1526-32. PubMed ID: 10589950
    [Abstract] [Full Text] [Related]

  • 6. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 7. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
    Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J, Grinyó JM, Friend P, Lawen J, Hartmann A, Schena FP, Lelong M, Burke JT, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2005 Nov 15; 80(9):1204-11. PubMed ID: 16314787
    [Abstract] [Full Text] [Related]

  • 8. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L, Ding T, Wang XX, Lin ZB, Chen G.
    Zhonghua Yi Xue Za Zhi; 2016 May 31; 96(20):1556-61. PubMed ID: 27266681
    [Abstract] [Full Text] [Related]

  • 9. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P.
    Transplantation; 2000 Apr 15; 69(7):1252-60. PubMed ID: 10798738
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.
    Transplant Proc; 2005 Mar 15; 37(2):693-6. PubMed ID: 15848504
    [Abstract] [Full Text] [Related]

  • 11. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 15; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 12. Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine.
    Machado PG, Felipe CR, Park SI, Garcia R, Moreira S, Casarini D, Franco M, Alfieri F, Tedesco-Silva H, Medina-Pestana JO.
    Braz J Med Biol Res; 2004 Sep 15; 37(9):1303-12. PubMed ID: 15334195
    [Abstract] [Full Text] [Related]

  • 13. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.
    MacDonald AS, RAPAMUNE Global Study Group.
    Transplantation; 2001 Jan 27; 71(2):271-80. PubMed ID: 11213073
    [Abstract] [Full Text] [Related]

  • 14. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, Shoker A, Wilczek H, Jamieson NV, Lelong M, Brault Y, Burke JT, Scarola JA, Rapamune Maintenance Regimen Study Group.
    Transplant Proc; 2009 Jan 27; 41(6):2339-44. PubMed ID: 19715914
    [Abstract] [Full Text] [Related]

  • 15. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.
    Machado PG, Felipe CR, Hanzawa NM, Park SI, Garcia R, Alfieri F, Franco M, Silva HT, Medina-Pestana JO.
    Clin Transplant; 2004 Feb 27; 18(1):28-38. PubMed ID: 15108768
    [Abstract] [Full Text] [Related]

  • 16. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J, Kahan BD.
    Transplant Proc; 2011 Dec 27; 43(10):3657-68. PubMed ID: 22172822
    [Abstract] [Full Text] [Related]

  • 17. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH.
    Int J Artif Organs; 2009 Jun 27; 32(6):371-80. PubMed ID: 19670189
    [Abstract] [Full Text] [Related]

  • 18. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 19. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transpl Int; 2005 Jan 27; 18(1):22-8. PubMed ID: 15612979
    [Abstract] [Full Text] [Related]

  • 20. Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results.
    Ferreira AN, Machado PG, Felipe CR, Motegi SA, Hosaka BH, Tanaka MK, Kamura LA, Park SI, Garcia R, Franco M, Alfieri F, Casarini DE, Tedesco-Silva H, Medina-Pestana JO.
    Clin Transplant; 2005 Oct 27; 19(5):607-15. PubMed ID: 16146551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.